Zoetis has announced an agreement to acquire veterinary teleradiology platform VitalRADS, strengthening its Global Diagnostics portfolio and expanding AI-enabled diagnostic services for veterinary practices worldwide.
The acquisition adds 24/7 access to board-certified veterinary specialists through a cloud-based teleradiology platform, alongside mobile ultrasound, outpatient imaging, and cloud-based image storage services. The move supports Zoetis’ vision of building a comprehensive end-to-end Virtual Reference Laboratory for veterinary diagnostics.
Click here to join our WhatsApp channel here
VitalRADS serves more than 1,800 customers, including independent clinics, corporate veterinary practices, and universities, providing rapid interpretation of radiographs, CT scans, MRI scans, ECGs, and ultrasound studies across more than 25 animal species. Its AI-assisted workflows and quality assurance tools are expected to enhance diagnostic accuracy, streamline reporting, and improve clinical decision-making.
“Through 24/7 access to world-class veterinary radiologists, cardiologists, neurologists, and dentists, VitalRADS helps veterinarians identify conditions faster, inform clinical decision-making, and guide treatment plans,” said Jamie Brannan, Executive Vice President and Chief Commercial Officer at Zoetis. “By strengthening our diagnostics ecosystem beyond in-vitro testing and building a more complete end-to-end Virtual Lab offering for our customers, we’re advancing our strategic pursuit of opportunities that unlock new sources of growth.”
Also read: New Collaboration Enhances Healthcare Access for Employees and Families
“This is an important milestone for our team and a reflection of the value we provide to veterinary teams,” said Dr. Brian Poteet, Founder and Chief Executive Officer of VitalRADS. “We are proud of what we have accomplished and remain committed to delivering the high-quality service and support our clients rely on. As part of Zoetis’ Global Diagnostic
The acquisition also complements Zoetis’ growing AI-powered diagnostics portfolio, including its Vetscan Imagyst® and Vetscan Opticell™ platforms, further integrating specialist expertise with advanced digital technologies to support veterinarians and improve patient care.
The transaction is expected to close in the third quarter of 2026, subject to customary regulatory approvals. Financial terms were not disclosed.
